Completed PHASE2 INTERVENTIONAL 2-arm NCT01194453

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer (AP/GP)

A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study

Sponsor: Sun Yat-sen University

Conditions Efficacy Non-small Cell Lung Cancer

Interventions cisplatin, dexamethasone,vitamin B12, folic acid cisplatin, gemcitabine

Updated 7 times since 2017 Last updated: May 10, 2016 Started: Nov 30, 2009 Primary completion: Sep 30, 2010 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Efficacy and Non-small Cell Lung Cancer and is currently completed. Sun Yat-sen University leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China